Category Research

ReAlta Reports RLS-0071 Cuts Brain Inflammation in Preclinical HIE Model

ReAlta Life Sciences Publishes Preclinical Data Showing RLS-0071 Reduces Brain Inflammation in Neonatal Hypoxic-Ischemic Encephalopathy Model ReAlta Life Sciences, Inc., a clinical-stage biopharmaceutical company advancing therapies that rebalance the body’s inflammatory response, has announced the publication of new preclinical findings…

Read MoreReAlta Reports RLS-0071 Cuts Brain Inflammation in Preclinical HIE Model

Takeda Secures FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Streamline HYQVIA® Delivery

Takeda Gains FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Enhance HYQVIA® Administration Experience for Patients with Primary Immunodeficiency and CIDP Takeda (TSE:4502/NYSE:TAK), a global biopharmaceutical leader, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k)…

Read MoreTakeda Secures FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Streamline HYQVIA® Delivery

PolyActiva Expands Leadership to Accelerate U.S. Growth and Clinical Progress

PolyActiva Strengthens Executive Team to Accelerate U.S. Expansion and Advance Late-Stage Clinical Development of Sustained-Release Ocular Therapies PolyActiva, a clinical-stage biopharmaceutical company at the forefront of innovation in ocular drug delivery, has announced two key leadership appointments that signal a…

Read MorePolyActiva Expands Leadership to Accelerate U.S. Growth and Clinical Progress

Tempus Secures FDA 510(k) Clearance for AI-Powered ECG-Low EF Diagnostic Software

Tempus Secures FDA 510(k) Clearance for AI-Driven ECG-Low EF Software, Expanding Capabilities in Cardiovascular Risk Detection Tempus AI, Inc. (NASDAQ: TEM), a trailblazer in applying artificial intelligence to drive precision medicine forward, has reached a significant milestone in the cardiology…

Read MoreTempus Secures FDA 510(k) Clearance for AI-Powered ECG-Low EF Diagnostic Software

Veranex Launches MedTech’s First iCRO to Transform R&D Amid Tight Capital Climate

Veranex Launches Industry’s First Innovation CRO to Accelerate MedTech R&D in a Tight Capital Climate Veranex, a global leader in integrated product development and contract research services for medical technology, has officially launched the industry’s first Innovation CRO (iCRO) —…

Read MoreVeranex Launches MedTech’s First iCRO to Transform R&D Amid Tight Capital Climate

C2N Diagnostics Expands Alzheimer’s Blood Test Portfolio for Researchers

C2N Diagnostics Unveils Two Groundbreaking Blood Tests to Advance Alzheimer’s Research and Precision Diagnostics C2N Diagnostics, LLC, a trailblazer in brain health diagnostics, has announced the launch of two innovative plasma-based assays designed for Research Use Only, expanding its suite…

Read MoreC2N Diagnostics Expands Alzheimer’s Blood Test Portfolio for Researchers

EyeDura’s Sustained-Release Eye Drop Technology Earns Dual Industry Accolades

EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered prominent recognition across two of the ophthalmology industry’s most respected…

Read MoreEyeDura’s Sustained-Release Eye Drop Technology Earns Dual Industry Accolades

Takeda Reports Positive Phase 3 Results for Oveporexton in Narcolepsy Type 1

Takeda’s Oveporexton Achieves Landmark Phase 3 Success in Narcolepsy Type 1, Paving Way for First-in-Class Orexin Therapy Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced a major milestone in its development pipeline, revealing that its investigational oral therapy oveporexton (TAK-861) has…

Read MoreTakeda Reports Positive Phase 3 Results for Oveporexton in Narcolepsy Type 1